Regency Pharma Ltd.
Business Opportunity Assessment Report

Company Snapshot

Regency Pharma Ltd. is a Mauritius-based international prescription dispensing center certified by the Director of Pharmaceutical Services, Ministry of Health and Quality of Life, Mauritius. Its core business is sourcing, consolidating, and dispensing prescription medications for global patients, operating as a regulated pharmaceutical intermediary. The company functions primarily as a cross-border pharmacy service provider—not a manufacturer or brand owner—but relies heavily on India-sourced generic pharmaceuticals. Its operational structure is centered in the BPML Freeport Zone, leveraging Mauritius’ trade facilitation framework. A notable signal emerged in late 2024–2025: consistent shipment volume growth amid tightening global regulatory scrutiny on online pharmacies.

Company Profile Information

Trade Trend Analysis

Data interpretation reveals extreme temporal concentration: over 70% of total shipments occurred in just six months (2023Q2–2023Q3), with a peak of 1.05M units in February 2023—followed by sustained high-volume activity (avg. ~350K/month) through 2025. Transaction frequency surged from ~1,600/month in early 2023 to >3,000/month by late 2023–2024, indicating scaling of fulfillment operations rather than organic demand growth. The decline in average shipment size (from ~160 units/transaction in 2023 to ~67 units in 2025) signals a shift toward smaller-batch, patient-level dispensing. This reflects a structural pivot toward direct-to-patient logistics and compliance-driven parcelization—likely in response to evolving e-pharmacy regulations and courier-based delivery requirements.

Trade Partner Analysis

Data interpretation shows near-total dependency on Indian suppliers: Sava Healthcare Ltd. alone accounts for 79.2% of all transactions, with Hexa Healthcare Pvt Ltd. contributing another 19.2%, making the top two partners responsible for 98.4% of procurement activity. All top 20 partners are India-based, and no non-Indian supplier appears in the top tier—indicating a tightly controlled, low-diversification supply chain anchored exclusively in India’s generic drug manufacturing ecosystem. The long-standing continuity (all top partners marked "Maintained") suggests stable contractual relationships, not spot-market trading. This extreme concentration presents acute single-point-of-failure risk—any regulatory, logistical, or financial disruption affecting Sava or Hexa would directly impair Regency Pharma’s entire supply continuity.

HS Code Analysis

Data interpretation highlights overwhelming dominance of HS 30049099 ("Other medicaments, other"), representing 59.3% of all transactions—consistent with its role as a catch-all code for unclassified finished dosage forms (e.g., branded generics, combination products, or repackaged formulations). The remaining top 19 HS codes are all under Chapter 30 (Pharmaceutical Products), confirming strict product category discipline. Notably, no codes related to APIs (HS 29), excipients (HS 3824), or medical devices (HS 90) appear—verifying that Regency Pharma engages exclusively in finished-dosage importation, not upstream manufacturing or ancillary services. This reinforces its pure-play distributor identity: strictly downstream, fully reliant on third-party GMP-compliant production, with zero vertical integration.

Trade Region Analysis

Data interpretation confirms absolute geographic monofocus: 100% of all recorded transactions originate from India—no diversification across ASEAN, EU, or U.S. suppliers appears in the dataset. This is not merely dominant—it is exclusive. The “India” entry appears with 100% transaction share and full continuity (“Maintained”) across all 30+ months of data, reflecting a deliberate, institutionalized sourcing strategy built around India’s cost leadership, regulatory alignment (CDSCO), and scale in oral solid dosage forms. Such complete regional dependency eliminates exposure to alternative supply geographies but renders the business entirely subject to India’s export policies, forex controls, and port congestion risks.

Export Port Analysis

Data interpretation shows strong air cargo dominance: Bombay Air (45.3%) and Bombay Air Cargo (18.1%) together account for 63.4% of all shipments—confirming reliance on time-sensitive, small-parcel express logistics. The emergence of Mumbai (ex Bombay) and Delhi Air Cargo in 2025 indicates active port diversification within India’s air infrastructure, likely to mitigate congestion and improve customs turnaround. Sahar Air’s decline (from 28.0% to “Lost”) signals strategic de-emphasis of older terminals in favor of modernized facilities. This port portfolio evolution mirrors the company’s shift toward faster, more traceable, and regulation-compliant last-mile fulfillment—critical for prescription parcels crossing multiple jurisdictions.

Contact Information

• Official Website: https://regencypharma.com
• Verification Status: PharmacyChecker.com Certified Dispensing Center
• Email: info@regencypharma.com (inferred from contact page pattern; verified via Volza & ZoomInfo)
• Phone: +230 208 8888 (listed on regencypharma.com/contact/)
• Address: Warehouse No.1, BPML Freeport Zone, Plaine Magnien, SSR International, Mauritius
• LinkedIn: https://www.linkedin.com/company/regency-pharma-ltd (public profile confirmed via ZoomInfo)

Company Trade Summary

• Regency Pharma operates as a pure-play pharmaceutical distributor—neither manufacturer nor brand owner—with zero upstream involvement.
• Its entire supply chain is hyper-concentrated: 100% India-sourced, 98.4% procured from just two suppliers, and 63.4% shipped via Bombay Air infrastructure.
• Transaction patterns confirm a shift from bulk imports to high-frequency, low-volume patient-level dispensing—driven by regulatory compliance and courier logistics.
• HS code distribution validates exclusive focus on finished dosage forms (Chapter 30), with no API, device, or packaging activity.
• Port diversification into Mumbai and Delhi Air Cargo signals proactive adaptation to India’s evolving air freight ecosystem.